APA (7th ed.) Citation

Nagata, H., Tsukamoto, T., Kobayashi, T., Takahashi, R., Okano, A., Uchiyama, H., . . . Kuroda, J. (2025). The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma. International Journal of Clinical Oncology, 30(3), 593. https://doi.org/10.1007/s10147-025-02691-8

Chicago Style (17th ed.) Citation

Nagata, Hiroaki, et al. "The Real-world Efficacy and Safety of Frontline Therapy of Obinutuzumab Plus Bendamustine for Untreated High-tumor-burden Follicular Lymphoma." International Journal of Clinical Oncology 30, no. 3 (2025): 593. https://doi.org/10.1007/s10147-025-02691-8.

MLA (9th ed.) Citation

Nagata, Hiroaki, et al. "The Real-world Efficacy and Safety of Frontline Therapy of Obinutuzumab Plus Bendamustine for Untreated High-tumor-burden Follicular Lymphoma." International Journal of Clinical Oncology, vol. 30, no. 3, 2025, p. 593, https://doi.org/10.1007/s10147-025-02691-8.